Data Also Underscores Potential Benefits of
CyberKnife System Sub-millimeter Accuracy in Preserving Quality of
Life after Treatment for Prostate Cancer
MADISON,
Wis., March 26, 2024 /PRNewswire/
-- Accuray Incorporated (NASDAQ: ARAY) announced today that
new data presented at the 2024 Radiosurgery Society Meeting in
Chicago, Illinois support the use
of the CyberKnife® System in the treatment of high-risk
and recurrent prostate cancer. The studies expand on years of
published clinical follow-up with a large number of prostate cancer
patients with various stages of disease, as well as with those who
were previously treated with radiotherapy – supporting the system's
versatility and value to medical care teams.
"An extensive number of peer-reviewed scientific manuscripts
have been published reporting on CyberKnife prostate SBRT efficacy
and tolerability. This most recent RSS data demonstrates the
ongoing interest in advancing patient care with the system, based
on its ability to deliver the precision and accuracy necessary to
not just help men to survive prostate cancer but also to have a
meaningful quality of life post treatment," said Seth Blacksburg,
M.D., MBA, Chief Medical Officer at Accuray.
The CyberKnife System enables treatment of prostate cancer using
a form of radiation therapy called stereotactic body radiation
therapy (SBRT) - very precise, high doses of radiation are
delivered over a shorter duration than traditional treatments. The
system's precision enables clinicians to confidently treat the
prostate gland, which is situated near the sensitive bladder and
rectum, with SBRT.
CyberKnife Platform for Prostate Cancer: The
CyberKnife platform offers an effective treatment option for
prostate tumors in 4-5 sessions, compared to conventional radiation
therapy that usually requires approximately 30-40 sessions over
8-10 weeks. Data presented at the RSS meeting showed its ability
to:
- Effectively treat high-risk disease while preserving quality of
life. Study authors concluded, "At the 3-year follow-up mark,
favorable biochemical control was achieved, and patients had
largely recovered to near baseline urinary and bowel function . . .
These findings underscore the potential of SBRT as a convenient
treatment option for high-risk prostate cancer, offering promising
outcomes and preserving patient quality of life1."
- Provide a viable option with "a low incidence of short-term
genitourinary (GU) and gastrointestinal (GI) toxicities" for
reirradiation of locally recurrent prostate
cancer2.
The prostate gland can move unpredictably throughout the course
of treatment. In fact, the prostate has been documented to move as
much as 10 mm in as little as 30 seconds due to normal patient
bodily functions – such as filling of the bladder, gas in the
bowel, or even slight patient movement during the
procedure3,4,5,6, making the ability to track,
detect and correct for motion critically important.
The CyberKnife System, using advanced imaging and real-time
artificial intelligence (AI)-driven motion tracking and
synchronization treatment delivery, with the Accuray proprietary
Synchrony® technology, can track the tumor and
continually verify its position, automatically correcting and
adapting the radiation beam position for even the slightest
movement. For example, if the prostate moves during treatment the
CyberKnife® System detects this movement and
synchronizes the treatment delivery beam to the tumor's new
position in real-time.
About Accuray
Accuray is committed to expanding the powerful potential of
radiation therapy to improve as many lives as possible. We invent
unique, market-changing solutions designed to deliver radiation
treatments for even the most complex cases—while making commonly
treatable cases even easier—to meet the full spectrum of patient
needs. We are dedicated to continuous innovation in radiation
therapy for oncology, neuro-radiosurgery, and beyond, as we partner
with clinicians and administrators, empowering them to help
patients get back to their lives, faster. Accuray is headquartered
in Madison, Wisconsin, with
facilities worldwide. To learn more, visit www.accuray.com or
follow us on Facebook, LinkedIn, X, and YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited to, expectations related to the
ability of our systems to be an effective treatment option, patient
experiences and patient outcomes. These risks and uncertainties
include, but are not limited to, the effect of the current global
economic environment, including in connection to the COVID-19
pandemic, on the operations of the company and those of its
customers and suppliers; the company's ability to achieve
widespread market acceptance of its products; the company's ability
to develop new products or improve existing products to meet
customers' needs; the company's ability to anticipate or keep pace
with changes in the marketplace and the direction of technological
innovation and customer demands; reliance on third party
collaborators, partnerships, strategic alliances and joint
ventures; and such other risks identified under the heading "Risk
Factors" in the company's Quarterly Report on Form 10-Q, filed with
the Securities and Exchange Commission (the "SEC") on February 7, 2024, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future events.
The company assumes no obligation to update forward-looking
statements to reflect actual performance or results, changes in
assumptions or changes in other factors affecting forward-looking
information, except to the extent required by applicable securities
laws. Accordingly, investors should not put undue reliance on any
forward-looking statements.
|
1
"Health-Related Quality of Life Following Robotic Stereotactic Body
Radiation Therapy for High-Risk Prostate Cancer." Presenting author
Vaibhav Sharma, M.D., Resident Physician, Georgetown University
Hospital, Washington, DC, USA.
2 "Acute Toxicity Following PSMA-Directed Focal Salvage
Robotic SBRT for Local Recurrences Following Prior Robotic Prostate
SBRT." Presenting author Zachary Wilson, Medical Student,
Georgetown University Hospital, Washington, DC, USA.
3 Drexler and Furweger. "Quality assurance of a robotic,
image guided radiosurgery system." WC 2009, IFMBE Proceedings 25/I,
492-495, 2009.
https://link.springer.com/chapter/10.1007/978-3-642-03474-9_138.
4 Kilby W, Dooley JR, Kuduvalli G, Sayeh S, Maurer CR.
The CyberKnife® Robotic Radiosurgery System in 2010. Technology in
Cancer Research & Treatment. 2010;9(5):433-452.
doi:10.1177/153303461000900502.
5 Yu C, Main W, Taylor D, Kuduvalli G, Apuzzo ML, Adler
JR Jr. An anthropomorphic phantom study of the accuracy of
Cyberknife spinal radiosurgery. Neurosurgery. 2004
Nov;55(5):1138-49. doi: 10.1227/01.neu.0000141080.54647.11. PMID:
15509320.
6 Antypas C, Pantelis E. Performance evaluation of a
CyberKnife G4 image-guided robotic stereotactic radiosurgery
system. Phys Med Biol. 2008 Sep 7;53(17):4697-718. doi:
10.1088/0031-9155/53/17/016. Epub 2008 Aug 11. PMID:
18695294.
|
Media Contact:
Beth Kaplan
Public Relations Director, Accuray
+1 (408) 789-4426
bkaplan@accuray.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/new-data-from-two-clinical-studies-indicate-high-risk-and-recurrent-prostate-cancers-can-be-effectively-treated-in-5-days-using-the-accuray-cyberknife-system-302099017.html
SOURCE Accuray Incorporated